Nuvation Bio Inc (NUVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has a cash flow conversion efficiency ratio of -0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.07 Million) by net assets ($253.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Nuvation Bio Inc for the company's overall valuation and market capitalisation.
Nuvation Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nuvation Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvation Bio Inc ranked by their cash flow conversion efficiency. Explore Nuvation Bio Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Fuling Electric Power Industrial Co Ltd
SHG:600452
|
0.061x |
|
NRW Holdings Limited
F:3NR
|
0.169x |
|
Resolute Mining Ltd
AU:RSG
|
0.174x |
|
Chalet Hotels Limited
NSE:CHALET
|
0.125x |
|
OKE Precision Cutting Tools Co. Ltd. A
SHG:688308
|
-0.006x |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
0.041x |
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
0.014x |
|
John Wiley & Sons
NYSE:WLY
|
0.240x |
Annual Cash Flow Conversion Efficiency for Nuvation Bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2025. View today's stock price for Nuvation Bio Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.72 Million | $-173.43 Million | -0.567x | -101.74% |
| 2024-12-31 | $463.79 Million | $-130.41 Million | -0.281x | -150.23% |
| 2023-12-31 | $605.12 Million | $-68.00 Million | -0.112x | +23.41% |
| 2022-12-31 | $655.08 Million | $-96.11 Million | -0.147x | -60.50% |
| 2021-12-31 | $746.00 Million | $-68.19 Million | -0.091x | +46.18% |
| 2020-12-31 | $215.08 Million | $-36.53 Million | -0.170x | +18.15% |
| 2019-12-31 | $117.75 Million | $-24.43 Million | -0.207x | -125.06% |
| 2018-12-31 | $-744.00K | $-616.00K | 0.828x | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more